IRVING, Texas, Jan. 6, 2012 /PRNewswire/ -- Reata Pharmaceuticals, Inc. today announced that Warren Huff, President and CEO, will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 10, at 10:00 a.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.
Mr. Huff’s presentation will include an update on the development of bardoxolone methyl, a first-in-class antioxidant inflammation modulator (AIM) for patients with advanced chronic kidney disease. He will discuss data from the recent Phase 2b BEAM trial, which was published in the New England Journal of Medicine, as well as the status of the ongoing Phase 3 BEACON trial, a global study of 2,000 patients with advanced chronic kidney disease and type 2 diabetes.
In addition, Mr. Huff will provide an overview of the company’s recently announced agreement with Abbott to jointly develop and commercialize Reata’s portfolio of new AIMs worldwide. The collaboration includes a large number of molecules in a broad range of therapeutic areas. This is the company’s second partnership with Abbott.
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes, and suppress NFkB, the primary regulator of inflammatory genes. Reata is developing these compounds called antioxidant inflammation modulators (AIMs) with the goal of one day making them available to patients suffering from a broad range of diseases associated with inflammation and oxidative stress. Reata plans to build a stand-alone, fully integrated pharmaceutical company with a worldwide medical, commercial, and regulatory presence. For more information, please visit www.reatapharma.com.
Reata Contacts
Media: Matt Middleman or David Schull, matt.middleman@russopartnersllc.com, 212-845-4272; david.schull@russopartnersllc.com, 212-845-4271
Investors: Alan Roemer, aroemer@troutgroup.com, 1-646-378-2945
SOURCE Reata Pharmaceuticals, Inc.
